Pharmaceutical giant Eli Lilly is expanding its presence in southeast Wisconsin with a planned $3 billion investment at the Pleasant Prairie facility it acquired in 2022. The expansion will bolster the company’s injectable product manufacturing, create 750 new jobs, and allow Indianapolis-based Lilly to meet growing demand for medicines addressing obesity and diabetes.
Lilly plans to start construction on the expansion next year and will use advanced automation, including guided vehicles and robotics, to accelerate medicine production. The expanded facility will focus on manufacturing injectable medicines, device assembly, and packaging for multiple therapeutic areas.
The company’s investment is part of its efforts to modernize and enhance existing sites with the latest technology to increase manufacturing capacity. Eli Lilly has made historic investments in recent years, committing over $23 billion since 2020 to construct, expand, and acquire manufacturing sites worldwide.
Lilly’s expansion comes as demand for medicines addressing obesity and diabetes reaches an all-time high, leading to longer wait times for patients refilling their prescriptions. The company makes several such medicines, including Trulicity, Mounjaro, and Zepbound, which address type 2 diabetes and obesity.
Source: https://biztimes.com/eli-lilly-plans-3-billion-expansion-in-pleasant-prairie-will-add-750-jobs